Explore more publications!

Solomon Islands Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Solomon Islands Health Reporter.

Press releases published on November 7, 2025

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
Treace Announces Participation in Two Upcoming Investor Conferences
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
Celldex to Present at Upcoming Investor Conferences
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
Vor Bio to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Vaxart to Host Upcoming Conference Calls
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions